Yahoo Finance

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $12 from $10 and keeps an Outperform rating on the shares. The company ended FY24 on a “strong note,” beating expectations across the board, the analyst tells investors. The firm continues to think there is significant growth potential ahead for the company’s minimal residual disease business.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving strong buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ADPT:

• Stable Performance and Strategic Guidance Support Hold Rating for Adaptive Biotechnologies

• Adaptive Biotechnologies Shines in 2024 Earnings Call

• Adaptive Biotechnologies Reports 2024 Financial Performance

• Adaptive Biotechnologies sees FY25 operating expenses $340M-$350M

• Adaptive Biotechnologies reports Q4 EPS (23c), consensus (24c)